Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00251732 · ClinicalTrials.gov registry record · Phase 4
Role of Pain Modulation in GERD Patients Who Failed Standard Dose Proton Pump Inhibitors (PPI)
A Phase 4 study, sponsored by University of Arizona.
- Completed
- Registry status
- Phase 4
- Development phase
- 150
- Enrollment target
NCT00251732 is a Phase 4 study that has completed, run by University of Arizona. The registered enrollment target is 150 participants.
The verdict
NCT00251732, a Phase 4 study, has completed, sponsored by University of Arizona.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 150 participants
- Enrollment target
Study Summary
The main objective of this study is to evaluate the role of pain modulation in GERD patients who fail to obtain clinical relief with standard dose (once daily) PPI. The study will compare the efficacy of 1) standard dose PPI plus low-dose tricyclic antidepressant (TCA) to, 2) double dose PPI to, 3) standard dose PPI and placebo to determine the relative symptom resolution and health related quality of life in GERD patients who fail standard dose PPI and are randomly assigned to one of these three groups.
Interventions
- DRUG Standard dose (once daily) PPI plus low-dose antidepressant
- DRUG Double dose PPI plus evening placebo
- DRUG Rabeprazole , placebo, placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2005-03 |
| Est. Completion | 2010-05 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00251732
The ClinicalTrials.gov registry entry for NCT00251732 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Arizona, which has 349 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Standard dose (once daily) PPI plus low-dose antidepressant is the first listed.
NCT00251732 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00251732 about?
NCT00251732 is a clinical study titled "Role of Pain Modulation in GERD Patients Who Failed Standard Dose Proton Pump Inhibitors (PPI)". The main objective of this study is to evaluate the role of pain modulation in GERD patients who fail to obtain clinical relief with standard dose (once daily) PPI. The study will compare the efficacy of 1) standard dose PPI plus low-dose tricyclic antidepressant (TCA) to, 2) double dose PPI to, 3) ...
What is the current status of trial NCT00251732?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 150 participants. The study started on 2005-03. Estimated completion is 2010-05.
What interventions are being tested in trial NCT00251732?
The interventions under investigation include: Standard dose (once daily) PPI plus low-dose antidepressant (DRUG), Double dose PPI plus evening placebo (DRUG), Rabeprazole , placebo, placebo (DRUG).
Who is sponsoring clinical trial NCT00251732?
This trial is sponsored by University of Arizona, which has 349 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.